Monday, March 20, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

DynPort Awarded up to 90M for Phase 1 Clinical Trials

by Global Biodefense Staff
January 21, 2015

DynPort Vaccine Company (DVC), a Computer Sciences Corporation (CSC) company, has received a follow-on contract to continue supporting the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Valued at up to $90 million, the award is a 10-year Indefinite Delivery/Indefinite Quantity contract to support and conduct Phase 1 clinical trials of infectious disease therapeutics.

Under the agreement, DynPort and its teaming partners, Quintiles, Health Decisions and WCCT Global, will support and manage Phase 1 clinical trial units to assess the safety of investigational therapeutic products being studied by NIAID, and determine pharmacokinetic and pharmacodynamic properties, which will inform appropriate human dosing regimens.

As the prime contractor, DynPort will manage the overall program and clinical operations, quality assurance and co-development of protocols and concepts. Quintiles, Health Decisions and WCCT Global will provide clinical research and support services for the implementation and conduct of approved clinical trial protocols.

Trials will include therapeutic candidates for a broad range of infectious diseases, and investigational products tested will include those to protect against viral, bacterial, parasitic and fungal pathogens, including NIAID priority biodefense pathogens and emerging and re-emerging infectious diseases.

Under the existing contract with NIAID awarded in 2008, DVC has completed four Phase 1 trials, while continuing to progress on three others. DVC also developed study protocols and clinical trial concepts for NIAID under separate task orders. Adding Health Decisions and WCCT Global, both small businesses, to the new contract increases DVC’s access to Phase 1 units across the United States and provides greater flexibility and efficiencies to NIAID.

Tags: AntimicrobialsAntiviralsAwardsVaccines

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC